EP0493498A1 - Medicament comprising antamanide - Google Patents

Medicament comprising antamanide

Info

Publication number
EP0493498A1
EP0493498A1 EP90914794A EP90914794A EP0493498A1 EP 0493498 A1 EP0493498 A1 EP 0493498A1 EP 90914794 A EP90914794 A EP 90914794A EP 90914794 A EP90914794 A EP 90914794A EP 0493498 A1 EP0493498 A1 EP 0493498A1
Authority
EP
European Patent Office
Prior art keywords
antamanide
anta
mice
linear
immunosuppressive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90914794A
Other languages
German (de)
French (fr)
Inventor
Zbigniew Wieczorek
Ignacy Z. Siemion
Jerzy Trojnar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring AB
Original Assignee
Ferring AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring AB filed Critical Ferring AB
Publication of EP0493498A1 publication Critical patent/EP0493498A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • the present invention relates to Antamanide and/or a functional linear derivative thereof for use as an immunosuppressive agent, to the use of Antamanide and/or a functional linear derivative thereof for the preparation of a medicament for immunosuppressive treatment, to a method of treating a mammal, including man, in need of immunosuppressive treatment and to a pharmaceutical preparation comprising Antamanide and/or a functional linear derivative thereof.
  • Antamanide is a cyclic decapeptide isolated from the mushroom Amanita phalloides (Wieland T, et. al.
  • Antamanide is
  • Antamanide protects liver cells against poisons, such as ethanol, dimethyl sulfoxide, cysteamine, or phalloidin (Primmer, M. and Petzinger,
  • the present invention is based on the finding that Antamanide (ANTA) having the cyclic formula and a linear form thereof, i.e. H-Val-Pro-Pro-Ala-Phe-Phe--Pro-Pro-Phe-Phe-OH (ANTA-L) exhibit immunosuppressive activity.
  • Antamanide having the cyclic formula and a linear form thereof, i.e. H-Val-Pro-Pro-Ala-Phe-Phe--Pro-Pro-Phe-Phe-OH (ANTA-L) exhibit immunosuppressive activity.
  • Antamanide and/or a functional linear derivative thereof for use as an immunosuppressive agent.
  • a functional linear derivative thereof in conjunction with Antamanide, is intended to comprise all linear forms of Antamanide and C-terminal amides and esters of linear forms of Antamanide and/or N-acylated linear forms of Antamanide, as long as said derivatives exhibit an immunosuppressive activity.
  • Antamanide which has proved to be immunosuppressive, is H-Val-Pro-Pro-Ala-Phe-Phe-Pro-Pro-Phe-Phe-OH.
  • Antamanide and/or a functional linear derivative thereof for the preparation of a medicament for immunosuppressive treatment.
  • a method of treating a mammal comprising administering to said mammal a pharmacologically effective amount of Antamanide and/or a functional linear derivative thereof.
  • a pharmaceutical preparation comprising, as an active ingredient, Antamanide and/or a functional linear derivative thereof together with pharmaceutically acceptable carrier(s), excipient(s) and/or diluent(s).
  • the amount of Antamanide and/or a functional linear derivative thereof to be administered to a mammal in need of immunosuppressive treatment has to be decided by a physician who is experienced in immunosuppressive therapy.
  • the pharmaceutical preparation comprising Antamanide and/or a functional linear derivative thereof can be formulated into oral preparations or preparations for infusion using pharmaceutically acceptable carrier(s), excipient(s) and/or diluent(s) suitable for such preparations, but keeping in mind that Antamanide and linear forms thereof are insoluble in water.
  • the pharmaceutical preparation can e.g. comprise Antamanide and/or a linear derivative thereof in a pharmacologically effective amount suspended in an olive oil.
  • Antamanide and/or a functional linear derivative thereof exhibit an immunosuppressive activity, which is comparable to that of Ciclosporin (also called Cyclosporin A). Accordingly, Antamanide and/or a functional linear derivative thereof are to be used in medicaments for immunosuppressive treatment of mammals, including man, for all indications where immunosuppressive treatment is warranted. Examples of when immunosuppressive treatment is warranted is for the prevention of allograft rejection after organ transplantation and bone marrow transplantation, prophylactic or therapeutic treatment of graft-versus-host ⁇
  • GVDH systemic lupus erythematosus
  • SLE systemic lupus erythematosus
  • RA rheumatoid arthritis
  • Cyclic Antamanide having the formula can be obtained by isolation as described by Wieland
  • T et al (ibid.), or can be synthesized by any conventional method in the art of peptide chemistry.
  • the amino acid residues are coupled to each other by known techni ques, by using solid phase technique or in solution, forming a linear peptide (a linear form of Antamanide), which is then cyclized, also in per se known manner by activating the C-terminal and keeping the activated linear peptide in high dilution and low temperature for cyclization.
  • the cyclization is performed e.g. according to the well known azide method.
  • the crude peptide can be purified by crystallization.
  • BocPhe was attached to a chloromethylated resin (1% DVB) by the method of Gisin (Helv. Chim. Acta 56, 1481 (1973)).
  • Boc-Phe-resin was subjected to nine cycles of deprotection (TFA/CH 2 Cl 2 ), neutralization [(i-Pr) 2 -EtN/CH 2 Cl 2 ], coupling (BocAA-3 eq.; DCC-3 eq/CH 2 Cl 2 ), recoupling (BocAA-3 eq.; DCC-3 eq/CH 2 Cl 2 ) and termination ([CH 3 CO] 2 O/CH 2 Cl 2 ) performed in a peptide synthesizer.
  • Boc-decapeptide-resin was deprotected (TFA/CH 2 -Cl 2 ), neutralized [(i-Pr) 2 EtN/CH 2 Cl 2 ] and washed (CH 2 Cl 2 ) on-line.
  • the peptide was then cleaved from the resin in its linear form, followed by isolation and purification or transformation to its cyclic form by a suitable procedure in solution.
  • Solvent system 60 min gradient from 0 to 100%
  • Solvent system 60 min gradient from 0 to 100%
  • SRBC sin red blood cells
  • ANTA Cyclosporin A
  • CS-A Cyclosporin A
  • Solvents Mixture of Cremophor EL (SIGMA) [A trademark for a derivative of castor oil and ethylene oxide] and 94% ethanol (6.5:3.5); olive oil, PBS (phosphate buffer solution)
  • mice with ANTA intraperitoneally i. p.
  • ANTA was dissolved in the mixture of Cremophor and ethanol (cremophor), diluted at a desired concentration in PBS, and 0.2 ml of it was introduced i.p.
  • mice with ANTA per os directly to the stomach:
  • the immunosuppressive activity of ANTA was compared with that of CS-A dissolved in PBS.
  • mice were injected intraperitoneally with 0.2 ml of 10% SRBC in PBS 3 hours after the introduction of the first dose of reagents. After 4 days, the number of plaque forming cells (PFC) in the spleen was determined according to Mishell-Dutton (Mishell R.I., Dutton R.W.: J. Exp. Med., 1967, 126, 423.) The magnitude of the humoral immune response was expressed as the number of PFC per 10 splenocytes.
  • mice Each group of experimental animals consisted of 7 mice.
  • Control I - mice were treated with 0.2 ml of PBS
  • Control II - mice were treated with appropriate concentration of cremophor needed to dissolve 10 ⁇ g of ANTA
  • mice The results are expressed as a mean ⁇ SE of 7 mice.
  • mice The results are expressed as a mean ⁇ SE of 7 mice.
  • Antamanide on graft-versus-host reaction (GvH)
  • Hybride F 1 (C3H/Iiw x B 6 /Iiw) and female B 6 mice, 8-10 weeks old
  • Reagents ANTA, CS-A
  • F 1 (C3HxB 6 ) mice The first dose was introduced 3 hours before injection of parenteral cells, and the second dose was introduced 48 hours later intraperitoneally.
  • the immunosuppressive activity of ANTA was compared with that of CS-A.
  • mice Female B 6 mice were killed, their popliteal nodes were pressed through a plastic screen into PBS. Then, the cells were washed three times with PBS and resuspended in RPMI medium.
  • Hybride mice, F, (C 3 HxB 6 ) were injected subcutaneously in the left hind footpad with 5x10 6 parental lymphoid cells (B 6 ). After 7 days, draining lymph nodes were isolated and weighed. As a control, the weight of popliteal node isolated from the right leg was measured.
  • the intensity of GvH reaction was expressed as a ratio of weights of popliteal lymph nodes isolated from the left and right legs (index of GvH reaction).
  • mice The results are expressed as a mean ⁇ SE of 9 mice.
  • SRBC sin red blood cells
  • Reagents ANTA-L, Cyclosporin A (CS-A) (Sandimmun. ®
  • mice with ANTA-L per os Treatment of mice with ANTA-L per os (directly to the stomach):
  • ANTA-L dissolved in cremophor at a desire concentration was added to two ml of olive oil and 0.2 ml of it was introduced per os to the animal; the first dose 3 hours before the antigen, and the second dose 24 hours later.
  • the immunosuppressive activity of ANTA-L was compared with that of CS-A dissolved in PBS.
  • mice were injected intraperitoneally with 0.2 ml of 10% SRBC in PBS 3 hours after the introduction of the first dose of reagents. After 4 days, the number of plaque forming cells (PFC) in the spleen was determined according to Mishell-Dutton (Mishell R.I., Dutton R.W.: J. Exp. Med., 1967, 126, 423.) The magnitude of the humoral immune response was expressed as the number of PFC per 10 6 splenocytes.
  • mice Each group of experimental animals consisted of 7 mice.
  • Control I - mice were treated with 0.2 ml of PBS
  • Control II - mice were treated with appropriate concentration of cremophor needed to dissolved 10 ⁇ g of ANTA-L
  • mice The results are expressed as a mean ⁇ SE of 7 mice.
  • Hybride F 1 (C3H/Iiw x B 6 /Iiw) and female B 6 mice, 8-10 weeks old
  • Reagents ANTA-L, CS-A
  • F 1 (C3HxB 6 ) mice The first dose was introduced 3 hours before injection of parenteral cells, and the second dose was introduced 48 hours later intraperitoneally.
  • the immunosuppressive activity of ANTA-L was compared with that of CS-A.
  • mice Female B 6 mice were killed, their popliteal nodes were pressed through a plastic screen into PBS. Then, the cells were washed three times with PBS and resuspended in RPMI medium.
  • Hybride mice, F, (C 3 HxB 6 ) were injected subcutaneously in the left hind footpad with 5x10 parental lymphoid cells (B 6 ). After 7 days, draining lymph nodes were isolated and weighed. As a control, the weight of popliteal node isolated from the right leg was measured.
  • the intensity of GvH reaction was expressed as a ratio of weights of popliteal lymph nodes isolated from the left and right legs (index of GvH reaction).
  • mice The results are expressed as a mean ⁇ SE of 10 mice.

Abstract

Antamanide ayant la formule cyclique (I), et/ou un de ses dérivés linéaires fonctionnels, utilisé comme agent immunosuppresseur. L'invention concerne également l'emploi d'antamanide et/ou d'un de ses dérivés linéaires fonctionnels dans la préparation d'un médicament de traitement immunosuppresseur, ainsi qu'un procédé de traitement d'un mammifère, y compris l'homme, nécessitant un traitement immunosuppresseur consistant en l'administration audit mammifère d'une quantité pharmacologiquement efficace d'antamanide et/ou d'un de ses dérivés linéaires fonctionnels. L'invention concerne également une préparation pharmaceutique comprenant de l'antamanide et/ou un de ses dérivés linéaires fonctionnels, et un ou des support(s), excipient(s) et/ou diluent(s) pharmaceutiquement acceptables.Antamanid having the cyclic formula (I), and / or one of its functional linear derivatives, used as an immunosuppressive agent. The invention also relates to the use of antamanid and / or one of its functional linear derivatives in the preparation of an immunosuppressive treatment medicament, as well as a method of treatment of a mammal, including man. , requiring an immunosuppressive treatment consisting in the administration to said mammal of a pharmacologically effective amount of antamanid and / or of a linear functional derivative thereof. The invention also relates to a pharmaceutical preparation comprising antamanid and / or one of its functional linear derivatives, and one or more pharmaceutically acceptable carrier (s), excipient (s) and / or diluent (s).

Description

MEDICAMENT COMPRISING ANTAMANIDE
The present invention relates to Antamanide and/or a functional linear derivative thereof for use as an immunosuppressive agent, to the use of Antamanide and/or a functional linear derivative thereof for the preparation of a medicament for immunosuppressive treatment, to a method of treating a mammal, including man, in need of immunosuppressive treatment and to a pharmaceutical preparation comprising Antamanide and/or a functional linear derivative thereof.
Background
Antamanide is a cyclic decapeptide isolated from the mushroom Amanita phalloides (Wieland T, et. al.
Angew. Chem. Int. Ed. Engl. 7 , 204-208, (1969)). The chemical structure of Antamanide is
It is well known that Antamanide protects liver cells against poisons, such as ethanol, dimethyl sulfoxide, cysteamine, or phalloidin (Primmer, M. and Petzinger,
E., Artzneim.-Forsch. 25, 1423 (1975)).
Kessler, H., et al (Ang. Chemie Int. Ed. Engl.
25, 997-999 (1986)) showed that Antamanide in vitro
inhibits the uptake of cholate into hepatocytes.
We are not aware of any biological studies effected on linear forms of Antamanide.
Neither are we aware of any medicaments comprising Antamanide or linear forms thereof.
Description of the invention
The present invention is based on the finding that Antamanide (ANTA) having the cyclic formula and a linear form thereof, i.e. H-Val-Pro-Pro-Ala-Phe-Phe--Pro-Pro-Phe-Phe-OH (ANTA-L) exhibit immunosuppressive activity.
In one aspect of the invention there is provided Antamanide and/or a functional linear derivative thereof for use as an immunosuppressive agent.
The expression "a functional linear derivative thereof" in conjunction with Antamanide, is intended to comprise all linear forms of Antamanide and C-terminal amides and esters of linear forms of Antamanide and/or N-acylated linear forms of Antamanide, as long as said derivatives exhibit an immunosuppressive activity.
An example of such a functional linear form of
Antamanide, which has proved to be immunosuppressive, is H-Val-Pro-Pro-Ala-Phe-Phe-Pro-Pro-Phe-Phe-OH.
In another aspect of the invention there is provided the use of Antamanide and/or a functional linear derivative thereof for the preparation of a medicament for immunosuppressive treatment.
In still another aspect of the invention there is provided a method of treating a mammal, including man, in need of immunosuppressive treatment, comprising administering to said mammal a pharmacologically effective amount of Antamanide and/or a functional linear derivative thereof.
In yet another aspect of the invention there is provided a pharmaceutical preparation comprising, as an active ingredient, Antamanide and/or a functional linear derivative thereof together with pharmaceutically acceptable carrier(s), excipient(s) and/or diluent(s).
The amount of Antamanide and/or a functional linear derivative thereof to be administered to a mammal in need of immunosuppressive treatment has to be decided by a physician who is experienced in immunosuppressive therapy.
The pharmaceutical preparation comprising Antamanide and/or a functional linear derivative thereof can be formulated into oral preparations or preparations for infusion using pharmaceutically acceptable carrier(s), excipient(s) and/or diluent(s) suitable for such preparations, but keeping in mind that Antamanide and linear forms thereof are insoluble in water. The pharmaceutical preparation can e.g. comprise Antamanide and/or a linear derivative thereof in a pharmacologically effective amount suspended in an olive oil.
The present invention reveals that Antamanide and/or a functional linear derivative thereof exhibit an immunosuppressive activity, which is comparable to that of Ciclosporin (also called Cyclosporin A). Accordingly, Antamanide and/or a functional linear derivative thereof are to be used in medicaments for immunosuppressive treatment of mammals, including man, for all indications where immunosuppressive treatment is warranted. Examples of when immunosuppressive treatment is warranted is for the prevention of allograft rejection after organ transplantation and bone marrow transplantation, prophylactic or therapeutic treatment of graft-versus-host¬
-disease (GVDH), and autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and diabetes mellitus.
Cyclic Antamanide having the formula can be obtained by isolation as described by Wieland
T, et al (ibid.), or can be synthesized by any conventional method in the art of peptide chemistry. The amino acid residues are coupled to each other by known techni ques, by using solid phase technique or in solution, forming a linear peptide (a linear form of Antamanide), which is then cyclized, also in per se known manner by activating the C-terminal and keeping the activated linear peptide in high dilution and low temperature for cyclization. The cyclization is performed e.g. according to the well known azide method. The crude peptide can be purified by crystallization.
Synthesis of linear and cyclic Antamanide
H-Val-Pro-Pro-Ala-Phe-Phe-Pro-Pro-Phe-Phe-OH
The above linear peptide was synthesized by solid phase technique in a Beckman model 9090 peptide synthesizer using tert-butoxycarbonyl-protected amino acids (BocAA).
BocPhe was attached to a chloromethylated resin (1% DVB) by the method of Gisin (Helv. Chim. Acta 56, 1481 (1973)).
The Boc-Phe-resin was subjected to nine cycles of deprotection (TFA/CH2Cl2), neutralization [(i-Pr)2-EtN/CH2Cl2], coupling (BocAA-3 eq.; DCC-3 eq/CH2Cl2), recoupling (BocAA-3 eq.; DCC-3 eq/CH2Cl2) and termination ([CH3CO]2O/CH2Cl2) performed in a peptide synthesizer.
The Boc-decapeptide-resin was deprotected (TFA/CH2-Cl2), neutralized [(i-Pr)2EtN/CH2Cl2] and washed (CH2Cl2) on-line.
The peptide was then cleaved from the resin in its linear form, followed by isolation and purification or transformation to its cyclic form by a suitable procedure in solution.
The crude product of cyclization was then isolated and purified by the reversed phase high performance liquid chromatography.
The purity of the cyclic product was determined by analytical HPLC. Column: Bondapak Cl8 flowrate 1.0 ml/min
a) retention time 41.6 min
Solvent system: 60 min gradient from 0 to 100%
A in B
A: 80% acetonitrile in B
B: 0.1% TFA in H2O
b) retention time 7 min
Solvent system: 60 min gradient from 0 to 100%
A in B
A: methanol
B: 0.1% TFA in H2O
The structure of the linear product and the cyclic product, i.e. were confirmed by amino acid analysis and FAB-MS (fast atom bombardment mass spectrometry).
Immunosuppressive activity of cyclic Antamanide (ANTA) I. Effect of ANTA on the humoral immune response Materials and methods
Animals: CBA/Iiw mice 8-10 weeks old
Antigen: SRBC (sheep red blood cells)
Reagents: ANTA, Cyclosporin A (CS-A) (Sandimmun.®
Sandoz. Basel Switzerland)
Solvents: Mixture of Cremophor EL (SIGMA) [A trademark for a derivative of castor oil and ethylene oxide] and 94% ethanol (6.5:3.5); olive oil, PBS (phosphate buffer solution)
Treatment of mice with ANTA intraperitoneally (i. p).
ANTA was dissolved in the mixture of Cremophor and ethanol (cremophor), diluted at a desired concentration in PBS, and 0.2 ml of it was introduced i.p.
to the animal twice; the first dose 3 hours before the antigen, and the second dose 24 hours later. The immunosuppressive activity of ANTA was compared with that of CS-A dissolved in PBS.
Treatment of mice with ANTA per os (directly to the stomach):
One ml of ANTA dissolved in cremophor at a desired concentration was added to two ml of olive oil and introduced per os to the animal; the first dose 3 hours before the antigen, and the second dose 24 hours later.
The immunosuppressive activity of ANTA was compared with that of CS-A dissolved in PBS.
Immunization of mice with SRBC and performance
experiment:
Mice were injected intraperitoneally with 0.2 ml of 10% SRBC in PBS 3 hours after the introduction of the first dose of reagents. After 4 days, the number of plaque forming cells (PFC) in the spleen was determined according to Mishell-Dutton (Mishell R.I., Dutton R.W.: J. Exp. Med., 1967, 126, 423.) The magnitude of the humoral immune response was expressed as the number of PFC per 10 splenocytes.
Each group of experimental animals consisted of 7 mice.
The results obtained are shown in Tables 1 and 2.
TABLE 1
The number of PFC in the spleens of mice treated with two doses of Antamanide (ANTA), or Cyclosporin A (CS-A) i.p.
Reagent PFC/106 ± SE p
μg/mouse (Student test)
Control I 2827 165
Controll II 2817 88
ANTA
1 μg 1584 260 <0.01
10 μg 702 98 >0.001
CS-A
1 μg 1179 126 <0.001
10 μg 533 49 <0.001
Control I - mice were treated with 0.2 ml of PBS
Control II - mice were treated with appropriate concentration of cremophor needed to dissolve 10 μg of ANTA
The results are expressed as a mean ± SE of 7 mice.
TABLE 2
The number of PFC in the spleens of mice treated with two doses of Antamanide (ANTA) or Cyclosporin A (CS-A) per os
Reagent PFC/106 ± SE p
μg/mouse (Student test]
Controlx 2730 137
ANTA
10 μg 1338 243 <0.01
100 μg 535 51 <0.001
CS-A
10 μg 1112 184 <0.001
100 μg 383 47 <0.001
x As a Control olive oil was used.
The results are expressed as a mean ± SE of 7 mice.
II. Effect of ANTA on cellular immune response in vivo
Effect of Antamanide (ANTA) on graft-versus-host reaction (GvH)
Materials and methods
Animals: Hybride F1 (C3H/Iiw x B6/Iiw) and female B6 mice, 8-10 weeks old
Reagents: ANTA, CS-A
Solvents: Mixture - Cremophor EL (Sigma): 94% ethanol
(6.5:3.5) -(cremophor), PBS Treatment of mice with ANTA:
ANTA dissolved in cremophor was introduced into
F1 (C3HxB6) mice. The first dose was introduced 3 hours before injection of parenteral cells, and the second dose was introduced 48 hours later intraperitoneally. The immunosuppressive activity of ANTA was compared with that of CS-A.
Preparation of parental cells:
Female B6 mice were killed, their popliteal nodes were pressed through a plastic screen into PBS. Then, the cells were washed three times with PBS and resuspended in RPMI medium.
GvH test:
GvH reaction was performed according to Twist and Barnes (Twist V.S., Barnes R.D.: Transplantation, 1973, 15, 1982). Hybride mice, F, (C3HxB6) were injected subcutaneously in the left hind footpad with 5x106 parental lymphoid cells (B6). After 7 days, draining lymph nodes were isolated and weighed. As a control, the weight of popliteal node isolated from the right leg was measured.
The intensity of GvH reaction was expressed as a ratio of weights of popliteal lymph nodes isolated from the left and right legs (index of GvH reaction).
The results are given in Table 3.
TABLE 3
GvH reaction in mice treated with two doses of Antamanide (ANTA) or Cyclosporin A (CS-A) i.p.
Reagent GvH (index) ± SE p
μg/mouse (Student test)
Controlx 3.21 0.340
ANTA
1 μg 1.74 0.133 0.01
10 μg 1.27 0.169 0.001
CS-A
1 μg 2.09 0.379 0.02
10 μg 1.29 0.109 0.001
x As a Control cremophor was used at a concentration
needed to dissolve 10 μg of the peptide.
The results are expressed as a mean ± SE of 9 mice.
Immunosuppressive activity of linear Antamamide (ANTA-L)
I. Effect of linear Antamanide (ANTA-L) on the humoral immune response
Materials and methods
Animals: CBA/Iiw mice 8-10 weeks old
Antigen: SRBC (sheep red blood cells)
Reagents: ANTA-L, Cyclosporin A (CS-A) (Sandimmun.®
Sandoz, Basel Switzerland)
Solvents: Mixture of Cremophor EL (SIGMA) and 94% ethanol
(6.5:3.5); olive oil, PBS (phosphate buffer solution) Treatment of mice with ANTA-L per os (directly to the stomach):
One ml of ANTA-L dissolved in cremophor at a desire concentration was added to two ml of olive oil and 0.2 ml of it was introduced per os to the animal; the first dose 3 hours before the antigen, and the second dose 24 hours later. The immunosuppressive activity of ANTA-L was compared with that of CS-A dissolved in PBS.
Immunization of mice with SRBC and performance of the experiment:
Mice were injected intraperitoneally with 0.2 ml of 10% SRBC in PBS 3 hours after the introduction of the first dose of reagents. After 4 days, the number of plaque forming cells (PFC) in the spleen was determined according to Mishell-Dutton (Mishell R.I., Dutton R.W.: J. Exp. Med., 1967, 126, 423.) The magnitude of the humoral immune response was expressed as the number of PFC per 106 splenocytes.
Each group of experimental animals consisted of 7 mice.
The results obtained are shown in Table 4.
TABLE 4
The number of PFC in the spleens of mice treated with two doses of linear Antamanide (ANTA-L), or Cyclosporin A (CS-A) per os.
Reagent PFC/10 ± SE p
μg/mouse (Student test)
Control I 1788 219
Controll II 1693 133
ANTA-L
100 μg 501 150 0.001
CS-A
100 μg 561 88 0.001
Control I - mice were treated with 0.2 ml of PBS
Control II - mice were treated with appropriate concentration of cremophor needed to dissolved 10 μg of ANTA-L
The results are expressed as a mean ± SE of 7 mice.
II. Effect of ANTA-L on cellular immune response in vivo Effect of linear Antamanide (ANTA-L) on graft-versus reaction (GvH)
Materials and metόds
Animals: Hybride F1 (C3H/Iiw x B6/Iiw) and female B6 mice, 8-10 weeks old
Reagents: ANTA-L, CS-A
Solvents: Mixture - Cremophor EL (Sigma): 94% ethanol
(6.5:3.5) -(cremophor), PBS Treatment of mice with ANTA-L:
ANTA-L dissolved in cremophor was introduced into
F1 (C3HxB6) mice. The first dose was introduced 3 hours before injection of parenteral cells, and the second dose was introduced 48 hours later intraperitoneally. The immunosuppressive activity of ANTA-L was compared with that of CS-A.
Preparation of parental cells:
Female B6 mice were killed, their popliteal nodes were pressed through a plastic screen into PBS. Then, the cells were washed three times with PBS and resuspended in RPMI medium.
GvH test:
GvH reaction was performed according to Twist and Barnes (Twist V.S., Barnes R.D.: Transplantation, 1973, 15, 1982). Hybride mice, F, (C3HxB6) were injected subcutaneously in the left hind footpad with 5x10 parental lymphoid cells (B6). After 7 days, draining lymph nodes were isolated and weighed. As a control, the weight of popliteal node isolated from the right leg was measured.
The intensity of GvH reaction was expressed as a ratio of weights of popliteal lymph nodes isolated from the left and right legs (index of GvH reaction).
The results are given in Table 5. TABLE 5
GvH reaction in mice treated with two doses of linear Antamanide (ANTA-L), or Cyclosporin A (CS-A) i.p.
Reagent GvH (index) ± SE p
μg/mouse (Student test)
Cremophor 3.17 0.36
ANTA-L
10 μg 1.48 0.16 0.01
CS-A
10 μg 1.41 0.16 0.001
x As a Control cremophor was used at a concentration
needed to dissolve 10 μg of the peptide.
The results are expressed as a mean ± SE of 10 mice.

Claims

1. Antamanide having the cyclic formula and/or a functional linear derivative thereof, for use as an immunosuppressive agent.
2. Use of Antamanide and/or a functional linear derivative thereof, for the preparation of a medicament for immunosuppressive treatment.
3. A method of treating a mammal, including man, in need of immunosuppressive treatment comprising administrering to said mammal a pharmacologically effective amount of Antamanide having the cyclic formula and/or a functional linear derivative thereof.
4. A pharmaceutical preparation comprising, as an active ingredient, Antamanide having the cyclic formula
and/or a functional linear derivative thereof, together with pharmaceutically acceptable carrier(s), excipient(s) and/or diluent(s).
EP90914794A 1989-09-22 1990-09-17 Medicament comprising antamanide Withdrawn EP0493498A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8903117A SE8903117D0 (en) 1989-09-22 1989-09-22 MEDICINAL COMPREHENSIVE ANTAMANIDE
SE8903117 1989-09-22

Publications (1)

Publication Number Publication Date
EP0493498A1 true EP0493498A1 (en) 1992-07-08

Family

ID=20376948

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90914794A Withdrawn EP0493498A1 (en) 1989-09-22 1990-09-17 Medicament comprising antamanide

Country Status (7)

Country Link
EP (1) EP0493498A1 (en)
JP (1) JPH05500811A (en)
AU (1) AU6514190A (en)
CA (1) CA2066721A1 (en)
IE (1) IE903416A1 (en)
SE (1) SE8903117D0 (en)
WO (1) WO1991004269A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505790A (en) * 1967-10-17 1971-04-15 Boehringer Sohn Ingelheim Process for the production of new cyclic decapeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9104269A1 *

Also Published As

Publication number Publication date
IE903416A1 (en) 1991-04-10
CA2066721A1 (en) 1991-03-23
SE8903117D0 (en) 1989-09-22
AU6514190A (en) 1991-04-18
WO1991004269A1 (en) 1991-04-04
JPH05500811A (en) 1993-02-18

Similar Documents

Publication Publication Date Title
US10787486B2 (en) Template-fixed peptidomimetics
US5464816A (en) Method and pharmaceutical compositions for treating immunodeficiencies
CN1218958C (en) Novel cyclosporin with improved activity profile
JPS60215700A (en) Novel cyclosporins
NZ225041A (en) 11 residue cyclosporin
JPH0276821A (en) Pharmacological composition for percutaneous administration
US8501683B2 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
SE501677C2 (en) Biologically active vasopressin analogs, pharmaceutical preparations containing them and their use in the manufacture of drugs
Wieczorek et al. Immunosuppressive activity in the series of cycloamanide peptides from mushrooms
RU2299741C1 (en) Peptide normalizing metabolism in osseous and cartilage tissue, pharmaceutical composition based on thereof and method for its using
EP0493498A1 (en) Medicament comprising antamanide
WO1990007523A1 (en) Medicament comprising cyclolinopeptide a
JPS61130236A (en) Medicine containing fully synthetic alpha-peptide promoting exhaustion of sodium from human pericardium
JPH09502175A (en) Novel tripeptide useful for immunity and CNS therapy
US6187810B1 (en) Macrocyclic compounds made from suboxide units
EP0537291A1 (en) Method of treating nausea and emesis related to motion sickness
SE467410B (en) ANALOGS OF CYCLOLINOPEPTIDE AND USE THEREOF
JP2628082B2 (en) Immunosuppressants
Różycki et al. New cyclosporin a analogue: Synthesis and immunosuppressive activity
SK85794A3 (en) Peptides with organoprotective activity, process for their preparation and their use
EP0285883A2 (en) Bactobolin as a prophylactic or therapeutic agent for autoimmune diseases, and as an immuno-suppressive agent
CN105440104A (en) Transdermal administration system of polypeptide and related compounds
MXPA97007662A (en) Peptides and therapeutic agent for autoimmune diseases that contain my mis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940405